Tanvex Biopharma Inc. said its U.S. subsidiary, Tanvex Biopharma U.S.A. Inc., received an FDA complete response letter (CRL) on Jan. 3 for its TX-05 BLA, a biosimilar that references Roche AG’s ...
This function is critical to prevent chronic inflammation since defects in such clearance can lead to auto-inflammatory diseases and may contribute to metabolic syndrome. In all, NRG-4 secreted by WAT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback